InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The advantage of inhalation is that it delivers medicine in the “first pass” to cardiac tissue, presenting a small, but effective dose of drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and, more importantly, can be patient self-administered anywhere PAF episodes may occur.
The lead product under development is an inhaled therapy to treat paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs with a long history of efficacy and safety in a new dosing paradigm.
We are a team of highly-experienced, passionate teammates who have a strong track record of development. We are also supported by a world-class group of experts and advisors.